Medilink Midlands is proud to announce the successful launch of Cohort 1 of the Medilink Midlands Innovation Builder (MMIB), a revolutionary programme designed to accelerate the development of high-potential health and medtech ventures across the UK and internationally.
Developed in partnership with Christian Kumar, Medilink Midlands’ Entrepreneur in Residence, the MMIB programme delivers focused, short-term intensive sprint providing innovators with tailored business support, expert coaching, investor readiness preparation, and access to a powerful network of investors, partners, and sector specialists.
Five pioneering companies were selected for Cohort 1:
- Acies Medical
- Neuro20 Technologies Corp
- Peak Medtek Ltd
- PROSTPERIA
- XRnostics Limited
These ventures span a range of breakthrough innovations—from AI-enabled rehabilitation and next-generation diagnostics to advanced wearable technologies – positioning them as emerging leaders in the global healthtech landscape.
A key milestone was Venture Day, held on Tuesday 3rd June at the Birmingham offices of Medilink Midlands Patron Mills & Reeve. Each company pitched to a room of leading investors, healthcare stakeholders, and sector experts, demonstrating the impact of the MMIB programme and the real-world potential of the innovations it supports.
Christian Kumar commented:
This programme is more than mentorship—it’s commercial due diligence in action. We’re here to shape investor-ready, scalable ventures. A company emerging from MMIB carries a signal of credibility and strategic potential. Investors know the groundwork has been done.”
In addition to Venture Day, three cohort members – Acies Medical, Neuro20 Technologies Corp and PROSTPERIA were invited to present at the Med-Tech Innovation Conference and Expo in Birmingham, where Medilink Midlands was a headline sponsor. The event is the UK’s leading medtech industry showcase, offering invaluable exposure to national and international partners, investors and commercial leaders.
This high-profile platform underlines the added value of MMIB – combining expert-led development with lasting visibility and networked support through Medilink Midlands membership.
Melanie Davidson, CEO of Medilink Midlands, said:
“The Innovation Builder reflects our long-standing commitment to unlocking innovation and growth across the medtech and life sciences sector. “It’s about building ventures that are not only investor-ready, but also visible and connected—whether that’s in boardrooms, on conference stages, or across global markets.”
The MMIB programme is powered by a strong coalition of delivery partners and Medilink Midlands members, offering specialist input across IP, regulatory, legal, clinical, and commercial domains. This collaborative, ecosystem-driven approach ensures companies receive high-quality, targeted support to enable sustainable growth.
A second MMIB cohort is planned for Winter 2025. Innovators and organisations interested in applying or supporting future rounds are encouraged to register their interest via the Medilink Midlands website: www.medilinkmidlands.com or email mminnovationbuilder@medilinkmidlands.com.
